Targets › APRIL
1 program from 1 company in 1 trial: 1 Phase 1; Genitourinary; next expected readout Jun 2028.
Cytokine that binds to TNFRSF13B/TACI and to TNFRSF17/BCMA. Plays a role in the regulation of tumor cell growth. May be involved in monocyte/macrophage-mediated immunological processes. (UniProt, O75888)
Open in Phaseline: the race on APRIL, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Beijing Mabworks Biotech | MIL116 anti-APRIL monoclonal antibody | APRIL | Phase 1 | Immunoglobulin A Nephropathy | Jun 2028 |
Immunoglobulin A Nephropathy (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.